Trial Profile
A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients with Steroid-Resistant Primary Focal Segmental Glomerulosclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Fresolimumab (Primary)
- Indications Focal segmental glomerulosclerosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genzyme Corporation; Sanofi
- 05 Jan 2015 New source identified and integrated ( Mayo Clinic; 12-004196)
- 14 Dec 2014 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 18 Sep 2014 New trial record